08:07:21 EDT Thu 13 Aug 2020
Enter Symbol
or Name

Login ID:
Cognetivity Neurosciences Ltd
Symbol CGN
Shares Issued 41,447,022
Close 2018-09-10 C$ 0.42
Recent Sedar Documents

ORIGINAL: Cognetivity Neurosciences Announces Launch of Key Clinical Validation Trial of its AI-powered Dementia Detection Technology

2018-09-10 10:27 ET - News Release

Cognetivity Neurosciences Announces Launch of Key Clinical Validation Trial of its AI-powered Dementia Detection Technology

Canada NewsWire

VANCOUVER, Sept. 10, 2018/CNW/ - Cognetivity Neurosciences Ltd. (the "Company" or "Cognetivity") (CSE: CGN) (FWB:1UB)(OTCQB: CGNSF), a company developing a next-generation Artificial Intelligence-driven platform for the early detection of cognitive impairment, is pleased to announce the start of its key clinical validation trial. The trial is being carried out in relation to the detection of cognitive performance in Alzheimer's and pre-Alzheimer's patients and will take place in London, England.

This trial is part of the established process towards gaining clinical regulatory approval for the Company's proprietary Integrated Cognitive Assessment (ICA) platform, which will allow the ICA to be used in clinical environments. The ICA's attributes, sensitivity and use of Artificial Intelligence make it a highly-promising tool for allowing the screening of large numbers of people for early-stage cognitive impairment associated with conditions such as Alzheimer's and other related diseases including dementia.

The trial is being conducted at the South London and Maudsley (SLaM) NHS Foundation Trust, which has the largest mental health research and development portfolio in the UK, and in conjunction with the Institute of Psychiatry, Psychology & Neuroscience at King's College London. The principal investigator of the study is Professor Dag Aarsland, Chair of Old Age Psychiatry at King's College London, a notable global researcher in the field.

Professor Aarsland commented: "We are very pleased to be adding this study to our portfolio of trials and working with Cognetivity on validating this exciting technology. Early detection of cognitive impairment, potentially linked to dementia, is so important. While a diagnosis of dementia is devastating, for many people getting an early diagnosis can open the doors to treatment and support and also enable people to make decisions and plan for the future. Importantly, emerging pharmacological treatments for Alzheimer's and other diseases that cause dementia are most likely to be targeted during the very earliest stages of the disease, giving even greater impetus to the need to diagnose early."

Cognetivity's CEO and director, Dr Sina Habibi, said, "We are delighted to be starting this trial which is the result of a lot of hard work by our team. This is an important step in delivering a tool which we believe can help an enormous number of people, by allowing the earlier detection of the cognitive impairment associated with dementias and other conditions - a vital step in providing the best care, improving outcomes for patients and massively reducing payer costs. While we have already experimentally demonstrated the platform's ability to detect the early cognitive signs of Alzheimer's disease, the next notable stage is to go through the formal process of regulatory approval, which is required to show that the technology can be used safely in a clinical environment.  On successful conclusion of this trial we will be able to submit our results for regulatory approval in the USA and Europe. This will in turn allow us to fully commercialize our ICA platform and enable it to begin being used as a clinical tool by medical professionals."

AboutCognetivity Neurosciences Ltd.

Cognetivity is a technology company developing a cognitive testing platform, the Integrated Cognitive Assessment (ICA) for use in medical and commercial environments. Cognetivity's ICA uses Artificial Intelligence and machine learning techniques to help detect the earliest signs of impairment by testing the performance of large areas of the brain, potentially allowing early diagnosis of dementia. Cognetivity aims to develop the ICA through planned clinical studies to the market in North America and Europe.

For moreinformation, please visit: www.cognetivity.com

About King's College London and the Institute of Psychiatry, Psychology & Neuroscience

King's College London is one of the top 25 universities in the world (2017/18 QS WorldUniversity Rankings) and among the oldest in England. King's has more than 26,500 students (of whom nearly 10,400 are graduate students) from some 150 countries worldwide, and nearly 6,900 staff. The university is in the second phase of a £1 billion redevelopment programme which is transforming its estate. www.kcl.ac.uk

The Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King's College London is the premier centre for mental health and related neurosciences research in Europe. It produces more highly cited publications in psychiatry and mental health than any other university in the world (Scopus, 2016), with 12 of the most highly cited scientists in this field. World-leading research from the IoPPN has made, and continues to make, an impact on how we understand, prevent and treat mental illness and other conditions that affect the brain. www.kcl.ac.uk/ioppn


"Sina Habibi"

Sina Habibi
Chief Executive Officer and Director


The forward-looking information contained in this press release is made as of the date of this press release and, except as required by applicable law, the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking information,whether as a result of new information, future events or otherwise, except as may be required by law. By its very nature, such forward-looking information requires the Company to make assumptions that may not materialize or that may not be accurate. This forward-looking information is subject to known and unknown risks and uncertainties and other factors, which may cause actual results, levels of activity and achievements to differ materially from those expressed or implied by such information.

The Exchange does not accept responsibility for the adequacy or accuracy of this release

SOURCE Cognetivity Neurosciences Ltd

View original content: http://www.newswire.ca/en/releases/archive/September2018/10/c3290.html


Email: info@cognetivity.com; For media enquiries contact: Josh Stanbury, Email:josh@sjspr.co.uk

© 2020 Canjex Publishing Ltd. All rights reserved.